Weld Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Weld Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-31,093	Closed	-$718K	–	401
2020 Q4	$718K	Sell	31,093 -6,788	-18%	-$139K	0.28%	116
2020 Q3	$535K	Buy	+37,881	New	+$552K	0.21%	174
2019 Q4	–	Sell	-76,836	Closed	-$616K	–	720
2019 Q3	$616K	Buy	+76,836	New	+$834K	0.11%	309
2019 Q2	–	Sell	-19,242	Closed	-$262K	–	813
2019 Q1	$262K	Buy	+19,242	New	+$235K	0.05%	536

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weld Capital Management's FOLD Position: Q1 2021 in Review

Weld Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 31,093 shares — an estimated $718K sold.

Weld Capital Management first reported a position in FOLD in Q1 2019 and held it in 4 quarters. The position peaked at $718K in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Weld Capital Management reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Weld Capital Management sold 31,093 Amicus Therapeutics shares in Q1 2021, an estimated $718K.
Weld Capital Management first reported a position in Amicus Therapeutics in Q1 2019 and held it in 4 quarters.
Weld Capital Management's Amicus Therapeutics position peaked at $718K in Q4 2020.
259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Weld Capital Management's 13F filing for Q1 2021, filed 17 May 2021.